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Abstract The growth of cells is determined by the balance be- 
tween growth-stimulatory and growth-inhibitory signals. In the 
present study, we demonstrate that the transfection of NIH 3T3 
cells with a platelet-derived growth factor (PDGF-BIc-sis) gene 
induces resistance to the anticeHular effects of tumor necrosis 
factor (TNF). Human tumor cell lines that express elevated levels 
of c-sis (e.g. epidermoid carcinoma, A-431) are also TNF resis- 
tant, whereas those that express no significant levels of this gene 
(e.g. breast adenocarcinoma, MCF-7) are TNF sensitive. Trans- 
fection of cells with the c-sis gene leads to down-modulation of 
TNF receptors and also a decrease in intraceilular glutathione 
levels. Thus, our results demonstrate that over-expression of 
PDGF-BIc-sis by certain tumor cells can lead to their protection 
from the anticellular effects of TNF. 
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1. Introduction 
Tumor necrosis factor (TNF) is one of the most important 
growth-modulatory cytokines produced by almost all cell types 
of the immune system [1]. For some cells TNF is a growth 
factor, whereas for others it is a growth inhibitor. Although the 
anticellular effects of TNF are normally paracrine, the prolifer- 
ative effects could be either autocrine (as in neuroblastoma, 
ovarian carcinoma, and B cell lymphoma) or paracrine (as in 
normal human fibroblasts) [2-6]. Several tumor cell lines are 
highly sensitive to the antiproliferative effects of TNF, and 
others are quite resistant [5]. The various intracellular nd ex- 
tracellular factors that are responsible for this resistance are 
unclear, but roles for manganese uperoxide dismutase, trans- 
forming growth factor-c~ (TGF-c0, pp60 vsr', and HER-2/neu/ 
erb B2, and glutathione have been demonstrated [7-11 ]. Certain 
tumor cell lines that express TNF have also been found to be 
resistant to TNF by some undefned mechanism [12]. 
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Platelet-derived growth factor (PDGF) is a potent mitogen 
for cells of mesenchymal origin and consists of disulfide-linked 
dimers of two related (approximately 60% homologous at their 
amino acid sequence level) polypeptide chains designated A 
and B (for references ee [13]). Formation of either hetero- 
dimers or homodimers ofA and B chains are essential for their 
biological activities. A transforming gene from simian sarcoma 
virus (SSV), v-sis, has been shown to encode a protein that is 
structurally related to the B chain of PDGF, thus indicating a 
role for this growth factor in tumorigenesis. Indeed, the over- 
expression of PDGF-B/c-sis in murine fibroblasts causes cellu- 
lar transformation in vitro and generation of fibrosarcoma in
vivo [14]. Elevated levels of PDGF-B/c-sis have also been asso- 
ciated with cellular transformation [15,16] and shown to occur 
in human epithelial tumor cell lines derived from stomach, 
pancreas, breast, prostate, lung, glioblastomas, and fibrosar- 
coma (for references see [13]). 
The study of factors that enhance cellular growth and those 
that suppress growth should lead to a better understanding of 
the processes involved in the regulation of normal and aberrant 
cell proliferation. The differential growth-modulatory activities 
of TNF against different cell types may be a result of the 
regulation of cellular growth by the balance between stimula- 
tory and inhibitory signals. Previously, we showed that cells 
transfected with human protein tyrosine kinases, HER-2 or 
pp60 v~" or with growth factor TGF-~ which activates tyrosine 
kinase, develop resistance to TNF [9,10,17]. In the present 
study, we investigated the effects of another gene, PDGF-B/c- 
sis, on the growth-suppressing activity of TNF. We found that 
it also induced resistance to TNF. In contrast to pp60 ~-~", but 
similar to HER-2 kinase and TGF-c~, resistance induced by c-sis 
was accompanied by the modulation of TNF receptors. Cellu- 
lar resistance to TNF correlated with a decrease in intracellular 
glutathione l vels. 
2. Materials and methods 
2.1. Materials 
Gentamicin and fetal bovine serum (FBS) were obtained from Gibco, 
Grand Island, NY. DMEM was obtained from Whittaker MA Bio- 
products, Walkersville, MD. Bacteria-derived r combinant human TNF 
and murine interferon-?, (IFN-7) purified to homogeneity were kindly 
provided by Genentech, Inc., South San Francisco, CA. Other chemical 
agents were purchased from Sigma Chemical Co. (St. Louis, MO). 
2.2. Cells 
Human epidermoid carcinoma cells, A-431 (CRL 1555), and breast 
adenocarcinoma cells, MCF-7 (HTB 22), were obtained from American 
Type Culture Collection, Rockville, MD. Human PDGF-2/c-sis-trans- 
fected NIH3T3 cells and the neomycin-transfected ontrol ines were 
a gift of Dr. Stuart A. Aaronson from National Cancer Institute, 
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Bethesda, MD. These cells were transfected in the laboratory of Dr. 
Aaronson by the calcium phosphate method using plasmid pPDGF-B 
under the control of a retroviral promoter containing an entire coding 
region for human PDGF-2/c-sis [16]. NIH-3T3 cells expressing the neo 
gene (pSV-neo) were selected by their ability to grow in the presence 
of the neomycin analogue G418. Cells were routinely grown in DMEM 
supplemented with glutamine (2 mM), gentamicin (50/~g/ml), and FBS 
(10%) in a humidified incubator in 5% CO2 in air. Occasionally, the 
transfected cells were checked for neomycin resistance by including 
G418 (500/lg/ml) in the medium. 
2.3. Antiproliferative assays 
For growth inhibition assays, cells (5 × 103/well) were plated over- 
night in 0.1 ml of DMEM with 10% FBS in 96-well Falcon plates. The 
medium was then removed, and a serial dilution of human TNF was 
layered in 0.1 ml of the medium. After a 72-h incubation at 37°C, the 
viable cells were monitored by Crystal violet staining according to 
previously described procedure [3]. The relative cell viability was calcu- 
lated as the optical density in the presence of the treated sample divided 
by the optical density of the untreated control samples and expressed 
as a percentage. 
2.4. Receptor-binding assay 
Binding assays for TNF receptors were performed in 96-well micro- 
plates as described elsewhere [18]. 
2.5. Determination of  &tracellular glutathione levels 
The intracellular glutathione levels were determined by an ion-ex- 
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Fig. 2. Effect of TNF on the growth rate ofneo- (upper panel) and c-sis- 
(lower panel) transfected NIH 3T3 cells. 5 × l03 cells/well in 1 ml were 
incubated in the presence or absence of TNF (20 ng/ml) in 24-well plates 
at 37°C. At indicated times, cell number was determined by the Trypan 
blue exclusion method as described in section 2. All determinations 
were made in duplicate. 
TNF (ng/ml) 
Fig. 1. Antiproliferative ffects of different concentrations of TNF 
against neo- and c-sis-transfected NIH 3T3 cells. 5 × 103 cells/well in 0.1 
ml were incubated with varying concentrations of human TNF in 96- 
well plates at 37°C for 72 h. The relative cell viability was determined 
by staining with Crystal violet as described in section 2. All determina- 
tions were in triplicate. 
previously [19]. Briefly, 3 × 10 6 cultured cells were homogenized in 10% 
HC104 and centrifuged. The pellet was analyzed for protein by the 
method of Lowry, and the supernatant was analyzed for glutathione 
content. All determinations were made in triplicate, and the results were 
expressed as nmol glutathione/mg protein. 
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3. Results 
3.1. N IH-3T3 cells tramfected with PDGF-B/c-sis are resistant 
to TNF  
First we examined the antiproliferative effects of TNF  by 
Crystal violet uptake on NIH3T3 cells transfected with either 
neo (control) or c-sis. The control cells were growth inhibited 
by TNF  in a dose-dependent manner (Fig. 1), whereas c-sis- 
transfected cells were relatively resistant. At 20 ng/ml TNF, the 
growth inhibition of control- and c-sis-transfected cells was 
approximately 80 and 5%, respectively. 
Because c-sis-transfected cells grow faster than control cells, 
we also examined the effect of TNF  on the growth rate of cells 
as determined by the change in viable cell number over time. 
The results of this experiment, shown in Fig. 2, indicated that 
in the presence of TNF  the growth of control cells was inhibited 
by almost 3-fold for up to 6 days, whereas c-sis-transfected cells 
continued to proliferate in the presence of TNF  at a rate iden- 
tical to untreated cells. These results further confirm that 
PDGF-B transfection induces resistance to TNF. NIH-3T3 
cells transfected with the c-sis gene were also examined for 
morphology. As shown in Fig. 3, cells transfected with c-sis 
differ in morphology from that of the neo control cells, the 
latter appearing more spindle-shaped as compared to cells 
transfected with c-sis. 
3.2. PDGF-B expression in tumor cell lines correlates with 
sensitivity to TNF  
The human epithelioid carcinoma cell line A-431 has been 
shown to express an elevated level of mRNA for PDGF-B, 
whereas the human breast adenocarcinoma cell line MCF-7 
expresses no detectable l vels of the message [20]. To correlate 
this with our observation on c-sis-transfected cells, we exam- 
ined these cell lines for sensitivity to TNF. As shown in Fig. 4, 
the A-431 cell line was found to be almost as resistant o TNF  
as c-sis-transfected cells. In contrast, MCF-7 cells were as sen- 
sitive to the antiproliferative effects of TNF  as the neo control. 
3.3. Cellular resistance to TNF  by c-sis transfection causes 
down-modulation o f  TNF  receptors 
We have previously shown that TNF  resistance associated 
with transfection of cells with the HER2 oncogene or with 
n e o c -s i s  
None 
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3 Fig. 3. Effect of TNF on the morphology ofneo control and c-sis-transfected NIH 3T3 cells. 5 x l0 cells/well in 1 ml were incubated in the presence 
or absence of TNF (20 ng/ml) in 24-well plates at 37°C for 72 h, the medium was changed and the cells were photographed atx40 magnification. 
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Fig. 4. Effect of TNF on tumor cell lines which over-express PDGF-BI 
c-sis. 5 x 103 cells/well in 1 ml were incubated in the presence or absence 
of TNF (20 ng/ml) in 24-well plates at 37°C for 72 h and then cell 
viability was determined by Trypan blue exclusion as described in 
section 2. All determinations were in duplicate. 
TGF-~ correlates with down-modulation f TNF receptors 
[10,17]. Therefore, we decided to examine the effect of c-sis 
transfection of cells on the TNF receptors. The results hown 
in Fig. 5 indicate that there was a significant decrease in the 
binding of TNF  to c-sis-transfected cells as compared to the neo 
control. Scatchard analysis revealed that the decrease was 
mainly due to receptor number rather than receptor affinity. 
3.4. Cellular resistance to TNF  induced by c-sis correlates with 
an increase in intracellular glutathione levels 
We have reported that cell density-dependent [21] cellular 
resistance to TNF  and that induced by pp60 ..... [9] correlates 
with the decrease in intracellular glutathione levels; therefore, 
we examined glutathione levels in control and c-sis-transfected 
cells. There was approximately a 50% decrease in the glutathi- 
one contents of  the c-sis-transfected cells compared to the neo 
controls (Fig. 6). 
3.5. Cellular resistance to TNF  induced by c-sis cannot be 
reversed by IFN-T 
We and others have shown that IFNs can potentiate the 
antiproliferative effects of TNF  [22-26]. We therefore xamined 
the possibility that PDGF-B-induced cellular esistance to TNF  
could be overcome by IFN-7/. The results indicate that IFN-~" 
had no effect on the anticellular effects of TNF  on c-sis-trans- 
fected cells, but it did potentiate the effect on control cells (data 
not shown). 
4. Discuss ion 
We report here that transfection of N IH 3T3 cells with c-sis 
leads to resistance to the antiproliferative effects of TNF. The 
induction of resistance was accompanied by the modulation of 
TNF  receptors and with a decrease in intraceUular glutathione 
levels. Furthermore, the cellular resistance to TNF  could not 
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Fig. 5. Specific binding of labeled human TNF to neo- and c-sis-trans- 
fected NIH 3T3 cells. 1 × 10 6 cells in 0.1 ml in 96-well plates were 
incubated with different concentrations of labeled TNF either in the 
presence (non-specific binding) or absence (total binding) of 100 nM 
of unlabeled TNF for 1 h at 4°C. Cells were then centrifuged and 
washed three times, and cell-bound radioactivity counted. All determi- 
nations were made in triplicate. 
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Fig. 6. Intracellular glutathione l vels in neo- and c-sis-transfected NIH 
3T3 cells. Bars represent the glutathione l vels (nmol/mg protein) in 
neo- and c-sis-transfected NIH 3T3 cells. All determinations were made 
in triplicate. 
The molecular basis for the sensitivity of certain tumor cell 
types to TNF  and resistance of others is not understood. It 
appears that the expression of certain growth factors and genes 
could play an important role in this process. Previously, we 
showed that tumor cells that over-express tyrosine protein ki- 
nase HER-2 or pp60 'srC or with growth factor TGF-c~ are resis- 
tant to TNF  [9,10,17]. We now report that PDGF-B/e-sis ex- 
pression also induces TNF  resistance, and this may occur 
through modulation of TNF  receptors, as noted in the case of 
HER-2. c-sis mRNA is over-expressed in several different ypes 
of tumors and tumor cell lines, including glioblastoma, fibro- 
sarcoma, stomach carcinoma, pancreatic arcinoma, prostate 
carcinoma, and breast carcinoma (for references ee [13]). 
Human tumor cell line A-431 (epithelioid carcinoma), which is 
known to over-express PDGF-B [20] was also found to be 
resistant to TNF, but MCF-7 (breast carcinoma), which does 
not express this gene, was found to be sensitive. 
The mechanism by which PDGF-B/c-sis could induce resis- 
tance to TNF  is not clear. It has been shown, however, that 
TNF, but not IFN-7, drastically up-regulates the mRNA levels 
for PDGF-B chain in a dose-dependent manner in a number of 
pancreatic tumor cell lines [20]. PDGF is known to display 
mitogenic effects through interaction with its receptor, which 
leads to autophosphorylation. Like TGF-~, the PDGF recep- 
tor is also a tyrosine kinase. Our previous results indicated that 
cells transfected with tyrosine kinases such as HER-2 or 
pp60 v-st" become resistant o the anticellular effects of TNF  
[9,10]. It is therefore possible that the activation of tyrosine 
kinase by the PDGF-B chain is responsible for protection of 
cells from TNF. Recently we have shown that protein tyrosine 
phosphatases play an important role in TNF-mediated antipro- 
liferative effects [27]. Because the proliferative ffects of the 
PDGF-B chain homodimer are mediated through protein phos- 
phorylation whereas the antiproliferative effects of TNF  may 
require dephosphorylation, it is possible that the effect of c-sis 
on cellular resistance is due to the inactivation of the protein 
tyrosine phosphatase pathway. We also found that c-sis-medi- 
ated cellular esistance l ads to a decrease in intracellular gluta- 
thione levels. This is consistent with our recent report showing 
an association between cell density-dependent resistance to 
TNF  and to a decrease in intracellular GSH levels [21]. Since 
c-sis-transfected cells grow at a rate faster than control cells, 
TNF resistance may also be due to higher cell density. This is, 
however, less likely since subconfluent cultures were used for 
our studies. A decrease in glutathione was also observed in cells 
transfected with pp60 v'sr" [9]. These results, however, are incon- 
sistent with those showing tumor cells that develop resistance 
to chemotherapeutic agents, which leads to elevation of intra- 
cellular GSH levels [19,28]. As tumorigenesis a result of 
altered expression of multiple oncogenes and growth factors, 
it is possible that different mechanisms in different umor cells 
contribute to the induction of resistance to TNF. 
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